Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 8:19 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 5,139 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: AIDS (Acquired Immunodeficiency Syndrome) Clear all

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: Not listed
Enrollment: 17,444 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2027
U.S. locations: 62
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 32 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Placebo version of rgp120/HIV-1MN, Placebo version of rgp120/HIV-1SF2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 3 Days
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 36
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 23 more

Conditions: HIV/AIDS
Interventions: Know@Home, Self-test Kit; Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Social Support Mobilization, Individual Care Counseling; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV/AIDS
Interventions: Rise - Treatment Education; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV
Interventions: no intervention; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
Interventions: PEG-Interferon a-2b + Ribavirin; Drug
Lead sponsor: Hepatitis Resource Network; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Autologous HIV-1 ApB DC Vaccine; Biological
Lead sponsor: Sharon Riddler; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sexually Transmitted Infections
Interventions: STI/HIV Intervention Behavioral Intervention Program; Behavioral
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 30 Years
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Fayetteville, North Carolina • Tacoma, Washington

Conditions: HIV
Interventions: (FDC) ELV/COBI/FTC/TDF; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Paclitaxel; Drug
Lead sponsor: Baker Norton Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 9 Months
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 41
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 26 more

Conditions: HIV I Infection, Adiposity
Interventions: Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections
Interventions: Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more

Conditions: Human Immunodeficiency Virus, HIV Infections
Interventions: EnvDNA; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV Infections
Interventions: Dose adjustment of Kaletra; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 4 Years to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV-1 Infection
Interventions: Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 9
States / cities: Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more

Conditions: HIV Infections, AIDS
Interventions: Fuzeon; Drug
Lead sponsor: Trimeris; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV
Interventions: Video treatments; Behavioral
Lead sponsor: Public Health Solutions; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, Inflammation
Interventions: Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pre-Exposure Prophylaxis, Hiv, Men
Interventions: PrEP messages, Heath messages; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Substance Abuse Detection, HIV, Hepatitis B, Hepatitis C, Brief Intervention, HIV Infections
Interventions: Brief motivational intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Depression, HIV Infection
Interventions: Cognitive behavioral therapy (CBT); Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Torrance, California

Search by objective public record fields.

Consent for Use of Stored Patient Specimens for Future Testing

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

Implementation of Rapid HIV Self-Testing Among MSM Project

Mobilizing Social Network Resources for HIV Care Support

A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans

A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

Autologous Dendritic Cell Vaccine in HIV1 Infection

STI/HIV Intervention Behavioral Intervention Program

Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet

Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults

Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Study of Enfuvirtide in HIV-Positive Subjects

Scale-up of an Internet-Delivered Study for HIV+ Men

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM)

Brief Intervention for Drug Misuse in the Emergency Department

Cognitive Behavioral Therapy to Help HIV Infected Adults With Depression to Adhere to Antiretroviral Therapy